Q3 2024 Pulse Biosciences Inc Earnings Call Transcript
Key Points
- Pulse Biosciences Inc (PLSE) treated the first patients with Atrial Fibrillation (AF) using their Nano PFA cardiac surgery system in Europe, marking a significant milestone.
- The cardiac surgery system received US FDA breakthrough device designation for the treatment of AF, providing an accelerated pathway for regulatory approval.
- The company successfully completed a rights offering, raising $60 million in gross proceeds, with potential to raise an additional $66 million through warrant exercises.
- Pulse Biosciences Inc (PLSE) received FDA 510-K clearance for their CellFX percutaneous electrode system for soft tissue ablation, allowing for US market launch.
- The company has placed their system with seven US sites as part of a pilot program for benign thyroid nodule treatment, showing positive initial clinical experiences.
- GAAP net loss increased to $12.7 million in Q3 2024 from $10.6 million in the prior year period, indicating financial challenges.
- Non-GAAP net loss also rose to $9.4 million in Q3 2024 compared to $8.5 million in the prior year period.
- The increase in GAAP costs and expenses was driven by higher non-cash stock-based compensation and other administrative expenses.
- Despite progress, the company is still in the early stages of clinical trials for its three main products, with commercialization not expected until after pivotal studies in 2025.
- The company faces significant competition and challenges in gaining widespread adoption for its Nano PFA technology, particularly in the thyroid nodule treatment market.
Greetings and welcome to the Pulse Biosciences third quarter, 2024 financial results conference call. (Operator Instructions)
As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Trip Taylor Investor Relations. Thank you, sir. You may begin.
Thank you, operator. Before we begin, I would like to inform you that comments and responses to your questions during today's call reflect management's views as of today. October 30, 2024, only and will include forward-looking statements and opinion statements including predictions, estimates, plans, expectations and other similar information.
Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued earlier today and in our filings with the US Securities and Exchange Commission, our SEC filings can be found on our website or on the SECs website. Investors are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
